Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation.
In epithelial tissues such as kidney, mineralocorticoid receptors (MR) are protected against glucocorticoid occupancy by the enzyme 11 beta-hydroxysteroid dehydrogenase (11 beta HSD) type 2. If the enzyme is congenitally inactive, or blocked by carbenoxolone, physiologic glucocorticoids act as MR agonists in such tissues. In most nonepithelial tissues, including cardiomyocytes, 11 beta HSD2 is expressed at minimal levels; in these tissues physiologic glucocorticoids act as MR antagonists, with the basis for this tissue selectivity currently unknown. Vascular smooth muscle cells (VSMC) express MR and 11 beta HSD1/2, with 11 beta HSD1 reported to show uncharacteristic oxidase activity, so that VSMC thus constitute a potential physiologic aldosterone target tissue. Because mineralocorticoid/salt administration triggers marked inflammatory responses in coronary vasculature, we reasoned that VSMC (like epithelial) MR may be activated by glucocorticoids if the protective enzyme is blocked. We thus gave uninephrectomized rats 0.9% NaCl solution to drink, and deoxycorticosterone (DOC, as a single 20 mg sc dose) or carbenoxolone (CBX, 2.5 mg/d in the drinking solution). Both DOC and CBX increased systolic blood pressure, heart, and kidney weight, and expression of cyclooxygenase 2, ED-1-positive macrophages, and osteopontin, with effects of both DOC and CBX blocked by the selective MR antagonist eplerenone. These findings suggest that local glucocorticoid excess, reflecting lower VSMC 11 beta HSD1/2 activity may mimic systemic mineralocorticoid excess, and play a direct etiologic role in coronary vascular inflammatory responses under circumstances of a high salt intake.
Young
Morag J
MJ
Baker Medical Research Institute, Melbourne Prahran 3181, Australia.
Moussa
Leon
L
Dilley
Rod
R
Funder
John W
JW
D042842:11-beta-Hydroxysteroid Dehydrogenases; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002229:Carbenoxolone / Q000494:pharmacology; D006332:Cardiomegaly / Q000201:enzymology*; D003327:Coronary Disease / Q000201:enzymology; D003900:Desoxycorticosterone / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000077545:Eplerenone; D005355:Fibrosis; D006321:Heart / Q000033:anatomy & histology; D006913:Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors* / Q000502:physiology; D007668:Kidney / Q000033:anatomy & histology; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000201:enzymology / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D009392:Nephrectomy; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride / Q000008:administration & dosage; D012996:Solutions; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology; D014657:Vasculitis / Q000201:enzymology
D004791:Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D012996:Solutions; D013148:Spironolactone; D003900:Desoxycorticosterone; D012965:Sodium Chloride; D000077545:Eplerenone; D006913:Hydroxysteroid Dehydrogenases; D042842:11-beta-Hydroxysteroid Dehydrogenases; D002229:Carbenoxolone